A new view of carcinogenesis and an alternative approach to cancer therapy

Molecular Medicine

Volumn 16, Issue 3-4, 2010, Pages 144-153

  López Lázaro, Miguel ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

CANCER CELL; CANCER GENE THERAPY; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; DRUG TARGETING; GENETIC DISORDER; GENETIC VARIABILITY; GLYCOLYSIS; HUMAN; METABOLISM; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; GLYCOLYSIS; HUMANS; HYDROGEN PEROXIDE; NEOPLASMS; OXIDATIVE STRESS; OXYGEN;

EID: 77649135478     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00162     Document Type: Review

References (142)

1. Nature milestones in cancer. (2006) Nat. Rev. Cancer. 6:S8-9.
2. Nordling CO. (1953) A new theory on cancerinducing mechanism. Br. J. Cancer. 7:68-72.
3. Fardon JC. (1953) A reconsideration of the somatic mutation theory of cancer in the light of some recent developments. Science. 117:441-5.
4. Armitage P, Doll R. (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer. 8:1-12.
5. Nowell PC. (1976) The clonal evolution of tumor cell populations. Science. 194:23-8.
6. Fearon ER, Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell. 61:759-67.
7. Reddy EP, Reynolds RK, Santos E, Barbacid M. (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 300:149-52.
8. Parada LF, Tabin CJ, Shih C, Weinberg RA. (1982) Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 297:474-8.
9. Goldfarb M, Shimizu K, Perucho M, Wigler M. (1982) Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature. 296:404-9.
10. Bishop JM. (1987) The molecular genetics of cancer. Science. 235:305-11.
11. Stanbridge EJ. (1990) Identifying tumor suppressor genes in human colorectal cancer. Science. 247:12-3.
12. Folkman J, Hahnfeldt P, Hlatky L. (2000) Cancer: looking outside the genome. Nat. Rev. Mol. Cell Biol. 1:76-9.
13. Stoler DL, et al. (1999) The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl. Acad. Sci. U. S. A. 96:15121-6.
14. Iacobuzio-Donahue CA. (2009) Epigenetic changes in cancer. Annu. Rev. Pathol. 4:229-49.
15. Prehn RT. (1994) Cancers beget mutations versus mutations beget cancers. Cancer Res. 54:5296-300.
16. Jaffe LF. (2003) Epigenetic theories of cancer initiation. Adv. Cancer Res. 90:209-30.
17. Rasnick D, Duesberg PH. (1999) How aneuploidy affects metabolic control and causes cancer. Biochem. J. 340:621-30.
18. Rajagopalan H, Lengauer C. (2004) Aneuploidy and cancer. Nature. 432:338-41.
19. Hanahan D, Weinberg RA. (2000) The hallmarks of cancer. Cell. 100:57-70.
20. Hahn WC, Weinberg RA. (2002) Rules for making human tumor cells. N. Engl. J. Med. 347:1593-603.
21. Vogelstein B, Kinzler KW. (2004) Cancer genes and the pathways they control. Nat. Med. 10:789-99.
22. Garman KS, Nevins JR, Potti A. (2007) Genomic strategies for personalized cancer therapy. Hum. Mol. Genet. 16:R226-32.
23. van't Veer LJ, Bernards R. (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 452:564-70.
24. Hayden EC. (2009) Personalized cancer therapy gets closer. Nature. 458:131-2.
25. Ma WW, Adjei AA. (2009) Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 59:111-37.
26. Druker BJ, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-7.
27. Hehlmann R, Hochhaus A, Baccarani M. (2007) Chronic myeloid leukaemia. Lancet. 370:342-50.
28. Melo JV, Barnes DJ. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer. 7:441-53.
29. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59:225-49.
30. Kushi LH, et al. (2006) American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J. Clin. 56:254-81.
31. Smith RA, Cokkinides V, Eyre HJ. (2006) American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J. Clin. 56:11-25.
32. Lopez-Lazaro M. (2006) HIF-1: Hypoxia-inducible factor or dysoxia-inducible factor? FASEB J. 20:828-32.
33. Lopez-Lazaro M. (2006) Does hypoxia really control tumor growth? Cell Oncol. 28:327-9.
34. Lopez-Lazaro M. (2007) Why do tumors metastasize? Cancer Biol. Ther. 6:141-4.
35. Lopez-Lazaro M. (2007) Excessive superoxide anion generation plays a key role in carcinogenesis. Int. J. Cancer. 120:1378-80.
36. Lopez-Lazaro M. (2007) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 252:1-8.
37. Lopez-Lazaro M. (2008) The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med. Chem. 8:305-12.
38. Lopez-Lazaro M. (2009) Role of oxygen in cancer: looking beyond hypoxia. Anticancer Agents Med. Chem. 9:517-25.
39. Mathupala SP, Ko YH, Pedersen PL. (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 19:17-24.
40. Chesney J, et al. (1999) An inducible gene product for 6-phosphofructo-2-kinase with an AUrich instability element: role in tumor cell glycolysis and the Warburg effect. Proc. Natl. Acad. Sci. U. S. A. 96:3047-52.
41. Christofk HR, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230-3.
42. Gatenby RA, Gillies RJ. (2004) Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer. 4:891-9.
43. Warburg O. (1956) On the origin of cancer cells. Science. 123:309-14.
44. Chen Z, Lu W, Garcia-Prieto C, Huang P. (2007) The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr. 39:267-74.
45. Vander Heiden MG, Cantley LC, Thompson CB. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029-33.
46. Isidoro A, et al. (2004) Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J. 378:17-20.
47. Unwin RD, et al. (2003) Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics. 3:1620-32.
48. Matoba S, et al. (2006) p53 regulates mitochondrial respiration. Science. 312:1650-3.
49. Szatrowski TP, Nathan CF. (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794-8.
50. Burdon RH. (1995) Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med. 18:775-94.
51. Zieba M, et al. (2000) Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. Respir. Med. 94:800-5.
52. Lim SD, et al. (2005) Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate. 62:200-7.
53. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. (2009) Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J. 418:29-37.
54. Semenza GL. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:721-32.
55. Semenza GL. (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today. 12:853-9.
56. Lopez-Lazaro M. (2006) Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev. 15:2332-5.
57. Chandel NS, et al. (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J. Biol. Chem. 275:25130-8.
58. Lu H, Forbes RA, Verma A. (2002) Hypoxiainducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277:23111-5.
59. Cerutti PA. (1985) Prooxidant states and tumor promotion. Science. 227:375-81.
60. Klaunig JE, Kamendulis LM. (2004) The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 44:239-67.
61. Okamoto M, Kawai K, Reznikoff CA, Oyasu R. (1996) Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Cancer Res. 56:4649-53.
62. Suh YA, et al. (1999) Cell transformation by the superoxide-generating oxidase Mox1. Nature. 401:79-82.
63. Arnold RS, et al. (2001) Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc. Natl. Acad. Sci. U. S. A. 98:5550-5.
64. Church SL, et al. (1993) Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 90:3113-7.
65. Safford SE, Oberley TD, Urano M, St Clair DK. (1994) Suppression of fibrosarcoma metastasis by elevated expression of manganese superoxide dismutase. Cancer Res. 54:4261-5.
66. Yan T, Oberley LW, Zhong W, St Clair DK. (1996) Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res. 56:2864-71.
67. Zhang Y, Zhao W, Zhang HJ, Domann FE, Oberley LW. (2002) Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. Cancer Res. 62:1205-12.
68. Hyoudou K, et al. (2004) Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferaseexpressing melanoma cells. Clin. Cancer Res. 10:7685-91.
69. Ramanathan A, Wang C, Schreiber SL. (2005) Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. U. S. A. 102:5992-7.
70. Ishikawa K, et al. (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 320:661-4.
71. Irani K, et al. (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 275:1649-52.
72. Vafa O, et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell. 9:1031-44.
73. Sattler M, et al. (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 275:24273-8.
74. Kopnin PB, Agapova LS, Kopnin BP, Chumakov PM. (2007) Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res. 67:4671-8.
75. Park S, You X, Imlay JA. (2005) Substantial DNA damage from submicromolar intracellular hydrogen peroxide detected in Hpx- mutants of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 102:9317-22.
76. Radisky DC, et al. (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 436:123-7.
77. Dayal D, Martin SM, Limoli CL, Spitz DR. (2008) Hydrogen peroxide mediates the radiation-induced mutator phenotype in mammalian cells. Biochem. J. 413:185-91.
78. Jackson AL, Loeb LA. (2000) Microsatellite instability induced by hydrogen peroxide in Escherichia coli. Mutat. Res. 447:187-98.
79. Kovacic P, Jacintho JD. (2001) Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr. Med. Chem. 8:773-96.
80. Guengerich FP, Shimada T. (1998) Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res. 400:201-13.
81. Zangar RC, Davydov DR, Verma S. (2004) Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. Appl. Pharmacol. 199:316-31.
82. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3:187-97.
83. Semenza GL. (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg. Biomembr. 39:231-4.
84. Reshkin SJ, et al. (2000) Na+/H+ exchangerdependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J. 14:2185-97.
85. Harguindey S, Orive G, Luis PJ, Paradiso A, Reshkin SJ. (2005) The role of pH dynamics and the Na(+)/H(+) antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Biochim. Biophys. Acta. 1756:1-24.
86. Simchowitz L. (1985) Intracellular pH modulates the generation of superoxide radicals by human neutrophils. J. Clin. Invest. 76:1079-89.
87. Alexandre J, et al. (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int. J. Cancer 119:41-8.
88. Alexandre J, et al. (2006) Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J. Natl. Cancer Inst. 98:236-44.
89. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 67:3512-7.
90. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 94:2102-11.
91. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. (2005) Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 76:1439-53.
92. Ubezio P, Civoli F. (1994) Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells. Free Radic. Biol. Med. 16:509-16.
93. Ikeda K, et al. (1999) Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells. Biochem. Pharmacol. 57:1361-5.
94. Fang J, Nakamura H, Iyer AK. (2007) Tumortargeted induction of oxystress for cancer therapy. J. Drug Target. 15:475-86.
95. Simizu S, Takada M, Umezawa K, Imoto M. (1998) Requirement of caspase-3(-like) proteasemediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J. Biol. Chem. 273:26900-7.
96. Gorman A, McGowan A, Cotter TG. (1997) Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett. 404:27-33.
97. Ling YH, Liebes L, Zou Y, Perez-Soler R. (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 278:33714-23.
98. Perez-Galan P, et al. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantlecell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 107:257-64.
99. Renschler MF. (2004) The emerging role of reactive oxygen species in cancer therapy. Eur. J. Cancer. 40:1934-40.
100. Oh SY, et al. (2007) Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage. Mol. Cancer Ther. 6:2178-87.
101. Doroshow JH. (1986) Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc. Natl. Acad. Sci. U. S. A. 83:4514-8.
102. Pelicano H, Carney D, Huang P. (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 7:97-110.
103. Fruehauf JP, Meyskens FL, Jr. (2007) Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 13:789-94.
104. Schumacker PT. (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 10:175-6.
105. Wondrak GT. (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox. Signal. 11:3013-69.
106. Engel RH, Evens AM. (2006) Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front. Biosci. 11:300-12.
107. Hirpara JL, Clement MV, Pervaiz S. (2001) Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J. Biol. Chem. 276:514-21.
108. Chen Q, et al. (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. U. S. A. 102:13604-9.
109. Maeda H, et al. (2004) Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death. Differ. 11:737-46.
110. Djavaheri-Mergny M, Wietzerbin J, Besancon F. (2003) 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene. 22:2558-67.
111. Xu RH, et al. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65:613-21.
112. Pelicano H, Martin DS, Xu RH, Huang P. (2006) Glycolysis inhibition for anticancer treatment. Oncogene. 25:4633-46.
113. Lopez-Lazaro M. (2007) Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert. Opin. Ther. Targets. 11:1043-53.
114. Gatenby RA, Gillies RJ. (2007) Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol. 39:1358-66.
115. Bonnet S, et al. (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11:37-51.
116. Paul RJ, Bauer M, Pease W. (1979) Vascular smooth muscle: aerobic glycolysis linked to sodium and potassium transport processes. Science. 206:1414-6.
117. James JH, et al. (1996) Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle: implications for increased muscle lactate production in sepsis. J. Clin. Invest. 98:2388-97.
118. Lopez-Lazaro M, et al. (2005) Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 68:1642-5.
119. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ. (2009) Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res. 29:2127-36.
120. Estrela JM, Ortega A, Obrador E. (2006) Glutathione in cancer biology and therapy. Crit Rev. Clin. Lab Sci. 43:143-81.
121. Tew KD. (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:4313-20.
122. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. (2006) Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J. Clin. Oncol. 24:1761-9.
123. Zhang K, Mack P, Wong KP. (1998) Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int. J. Oncol. 12:871-82.
124. Arner ES, Holmgren A. (2006) The thioredoxin system in cancer. Semin. Cancer Biol. 16:420-6.
125. Nonn L, Berggren M, Powis G. (2003) Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res. 1:682-9.
126. Powis G, Mustacich D, Coon A. (2000) The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 29:312-22.
127. Aft RL, Zhang FW, Gius D. (2002) Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br. J. Cancer. 87:805-12.
128. Maschek G, et al. (2004) 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64:31-4.
129. Coleman MC, et al. (2008) 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic. Biol. Med. 44:322-31.
130. Lin X, et al. (2003) 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res. 63:3413-7.
131. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. (2007) 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 67:3364-70.
132. Hernlund E, et al. (2008) Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int. J. Cancer. 123:476-83.
133. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. (2000) Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism? Ann. N. Y. Acad. Sci. 899:349-62.
134. Ahmad IM, et al. (2005) Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J. Biol. Chem. 280:4254-63.
135. Jelluma N, et al. (2006) Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol. Cancer Res. 4:319-30.
136. Nath KA, et al. (1995) alpha-Ketoacids scavenge H2O2 in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. Am. J. Physiol. 268:C227-36.
137. Miwa H, Fujii J, Kanno H, Taniguchi N, Aozasa K. (2000) Pyruvate secreted by human lymphoid cell lines protects cells from hydrogen peroxide mediated cell death. Free Radic. Res. 33:45-56.
138. Ramakrishnan N, Chen R, McClain DE, Bunger R. (1998) Pyruvate prevents hydrogen peroxideinduced apoptosis. Free Radic. Res. 29:283-95.
139. Salahudeen AK, Clark EC, Nath KA. (1991) Hydrogen peroxide-induced renal injury. A protective role for pyruvate in vitro and in vivo. J. Clin. Invest. 88:1886-93.
140. Tuttle SW, Varnes ME, Mitchell JB, Biaglow JE. (1992) Sensitivity to chemical oxidants and radiation in CHO cell lines deficient in oxidative pentose cycle activity. Int. J. Radiat. Oncol. Biol. Phys. 22:671-5.
141. Averill-Bates DA, Przybytkowski E. (1994) The role of glucose in cellular defences against cytotoxicity of hydrogen peroxide in Chinese hamster ovary cells. Arch. Biochem. Biophys. 312:52-8.
142. Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108.